OncoMatch/Clinical Trials/NCT06835569
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Is NCT06835569 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ALTA3263 and cetuximab for cancer.
Treatment: ALTA3263 · cetuximab — The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care therapy — appropriate to tumor type and stage
Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
Cannot have received: KRAS inhibitor
Exception: certain exceptions are described in the full study protocol
Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Orlando, Florida
- Research Site · Boston, Massachusetts
- Research Site · Boston, Massachusetts
- Research Site · New York, New York
- Research Site · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify